May 24, 2022 7:36am

With the sector being whipsawed again – very few ups or and more than many downs

Pre-open indications: 1 Puff/Pump/Promote and 5 Watch-Out-Below (doesn’t say SELL into further Losses)

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 7:30 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.56% (-177 points), S&P futures are DOWN -0.91% (-36 points) and NASDAQ futures are DOWN -1.46% (-175 points) early in the pre-open – so far,


Stock futures are lower and falling in pre-market trading on Tuesday morning,

European stocks also dropped in almost all sectors as major bourses slid into the red,

Asia-Pacific stocks declined led by China with Japan and South Korea.



The major stock indexes posted solid gains Monday. Monday's action was a step in the right direction following last week's heavy selling, but it wasn't enough to switch the market status back into a confirmed uptrend. <IBD>

Today’s downside moves came a day after indexes staged a rebound from last week’s market sell-off, which saw the Dow hit its first eight-week losing streak since 1923, and the S&P 500 briefly fall into bear market territory on an intra-day basis.

Even though the underlying uptrend remains intact, it's time to play defense and maintain a cautious stance after heavy selling last week.


RegMed Investors’ (RMi) closing bell: “cell and gene therapy sector declines as market indexes incline. Another I told you so, as I saw, felt and said - HOLD as a dive was coming having also stated, “What “pops” in the morning session will more than probably fade by the close.”

Ebb and flow –

Q2/22 –

May - 8 positive and 7 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


RegMed Investors (RMi) - Q1/22 Cell and Gene Therapy Earnings Scorecard Results … -- added Brainstorm Cell Therapeutics (BCLI), Homology Medicine FIXX) and Biostage (BSTG)


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

The downslide is coming and upon us – so I am NOT saying SELL into a downdraft nor am I espousing BUYs. Although…

Alnylam Pharmaceuticals (ALNY) after being dragged-down on Monday shows some life with a +$0.42 or +0.32% upside move based on news from yesterday.

Watch-out below:

Vericel (VCEL) closed down -$0.18 with a negative -$0.38 or -1.44% pre-open indication

Intellia (NTLA) closed down -$0.42 with a negative -$1.84 or -3.89% pre-open indication

CRISPR Therapeutics (CRS)) closed down -$1.63 with a negative -$0.71 or -1.30%

Editas Medicine (EDIT) closed down -$0.13 with a negative -$0.37 or -3.40% pre-open indication,

Beam Therapeutics (BEAM) closed down -$0.20 with a -$0.99 or -2.83% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat again with zero shares traded after Fridays with 916 shares traded after Thursday’s +$0.63 with 916 shares traded, Wednesday’s +$0.10 with 980 shares traded and Tuesday’s -$0.89 following the previous Monday’s flat.

WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing.  is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?



The BOTTOM LINE: I am not always right but, more than frequently not wrong … I just DO NOT trust this market … too much fear and panic. This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resilience or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …

I have NOT seen ANY step-up of declining company investment by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

I caution investors that the severe share pricing’s – technical and fundamental damage has been suffered these past several months which will take longer than a few good sessions to repair.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.


All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.